This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
The Zacks Analyst Blog Highlights: Chevron, Wells Fargo, Eli Lilly, FedEx and Valero
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Chevron, Wells Fargo, Eli Lilly, FedEx and Valero
Allergan Recalls Taytulla Oral Contraceptives, Stock Down
by Zacks Equity Research
Allergan (AGN) recalls some sample packs of Taytulla oral birth control pills. Shares decline.
Novo Nordisk's Oral Ozempic Positive in Diabetes Study
by Zacks Equity Research
Novo Nordisk's (NVO) oral formulation of Ozempic acts better in lowering blood sugar levels in adults with type II diabetes than Eli Lilly's Jardiance, in the second phase IIIa study, PIONEER 2.
Dow 30 Stock Roundup: GE's Transportation Unit to Merge With Wabtec, J&J & Glaxo's HIV Drug Gets EU Approval
by Swarup Gupta
The Dow endured another volatile week marked by key geopolitical developments.
FDA Confirms September Action Date for Teva's Migraine Drug
by Zacks Equity Research
Teva (TEVA) confirms that FDA has extended the goal date of the Biologics License Application (BLA) for fremanezumab to September from mid-June.
Merck's Keytruda Shows Survival Benefit in Squamous NSCLC
by Zacks Equity Research
Merck's (MRK) Keytruda in combination with chemotherapy demonstrates better OS and PFS in first-line metastatic squamous NSCLC compared to chemotherapy alone.
Why Is Eli Lilly (LLY) Up 2.7% Since Its Last Earnings Report?
by Zacks Equity Research
Eli Lilly (LLY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Eli Lilly Gets FDA Approval for Taltz in Genital Psoriasis
by Zacks Equity Research
Eli Lilly (LLY) gets FDA approval for label expansion of its psoriasis injection Taltz to include data for psoriasis involving the genital area.
Amgen's Label Expansion Application for Prolia Gets FDA Nod
by Zacks Equity Research
Amgen (AMGN) announces FDA approval for its regulatory application seeking label expansion for Prolia.
Migraine Space in Focus as AMGN/NVS' Aimovig Gets FDA Nod
by Zacks Equity Research
Migraine is one of the top 10 causes of years lived with disability globally. With Aimovig receiving FDA approval for treatment of migraine, investors' attention is on future regulatory decisions.
Pharma Stock Roundup: Zoetis to Buy Abaxis, NVS Gets FDA Nod for Migraine Drug
by Zacks Equity Research
Novartis' (NVS) CGRP antibody, Aimovig gains FDA approval for prevention of migraine. Zoetis (ZTS) and Lilly (LLY) announce deals to buy smaller companies.
AstraZeneca's (AZN) Q1 Earnings & Sales Miss, Stock Down
by Zacks Equity Research
AstraZeneca (AZN) misses earnings and sales estimates in the first quarter. It maintains its previously issued outlook for 2018.
Amgen's Migraine Drug Aimovig Gets FDA Approval, Shares Up
by Zacks Equity Research
Amgen's (AMGN) preventive treatment for migraine, Aimovig, gets approval in the United States.
Roche Tecentriq Combo Achieves Longer Overall Survival Rate
by Zacks Equity Research
Roche's (RHHBY) immuno-oncology drug, Tecentriq, in combination with Avastin and chemotherapies leads to significantly longer overall survival rates in treatment-naive NSCLC patients.
Eli Lilly's Cluster Headache Candidate Succeeds in Phase III
by Zacks Equity Research
Eli Lilly's (LLY) galcanezumab meets the primary endpoint in a late-stage study evaluating it for the prevention of episodic cluster headache.
Eli Lilly (LLY) to Buy AurKa Pharma, Expand Cancer Pipeline
by Zacks Equity Research
Eli Lilly (LLY) to buy an early phase oncology asset, AK-01, from AurKa Pharma to expand its oncology pipeline.
Nektar (NKTR) Q1 Loss Wider Than Expected, Sales Soar Y/Y
by Zacks Equity Research
Nektar (NKTR) reports wider-than-expected loss in Q1 while revenues rise substantially year over year. It collaborates with Bristol-Myers for advancing immuno-oncology and immunology pipeline.
AstraZeneca's (AZN) Asthma Drug Fasenra Fails in COPD Study
by Zacks Equity Research
AstraZeneca's (AZN) asthma drug Fasenra (benralizumab) fails to meet the primary endpoint in a late-stage study evaluating it for a new indication - COPD.
Celldex (CLDX) Q1 Loss Wider Than Expected, Shares Down
by Zacks Equity Research
Celldex (CLDX) reports wider-than-expected loss in Q1 but sales beat estimates. It discontinues development of its lead pipeline candidate following its failure in breast cancer study.
Radius Health (RDUS) Incurs Narrower-Than-Expected Q1 Loss
by Zacks Equity Research
Radius Health (RDUS) narrower-than-expected loss in the first quarter was encouraging as sales of lead drug Tymlos pick up amid competition.
Trump Announces Plan to Reign In Drug Prices and Pharma Stocks Rally.
by David Borun
Bid U.S. drug makers are seen as largely spared the worst in the Trump Administrations plans to control drug prices.
AVEO Pharmaceuticals (AVEO) Q1 Loss Wider Than Expected
by Zacks Equity Research
AVEO Pharmaceuticals (AVEO) reports wider-than-expected loss in the first quarter while revenues come almost in-line with estimates. Data from TIVO-3 study postponed. Shares down.
What's in Store for Radius Health (RDUS) in Q1 Earnings?
by Zacks Equity Research
Investors are expected to focus on the uptake of lead drug, Tymlos, and other pipeline developments when Radius Health (RDUS) reports results for the first quarter.
Q1 Earnings Drag Pharma ETFs Down
by Sweta Killa
Pharma ETFs saw terrible trading over the past month as mediocre results failed to boost confidence in the space, pushing many funds to 52-week lows.
Top Ranked Growth Stocks to Buy for May 4th
by Zacks Equity Research
Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, May 4th: